Effective, convenient solutions for Female Sexual Interest/Arousal Disorder

Our mission is to provide women with pharmaceutical solutions for Female Sexual Interest/Arousal Disorder (FSIAD) to help them feel like themselves again.

FSIAD is a type of sexual dysfunction characterized by a lack of, or significantly reduced, sexual interest and/or arousal. As with other types of sexual dysfunction, FSIAD can be distressing and can affect a person’s self-esteem, relationships, and overall well-being.

Want to learn more about FSIAD?

About FSIAD

Women's experiences withFemale Sexual Interest/Arousal Disorder

Low desire is the most commonly
reported sexual complaint among women (Laumann et al. 1999, Laumann et al. 2005, Shifren et al. 2008, McCabe et al. 2015, Zheng et al. 2016)

Many women don’t know that
low sexual desire is a treatable
medical condition 
(Kingsberg 2014)

Women’s options for sexual disorder
treatments are more than
20 years behind options for men

Women's sexual health is complex - treatments for fsiad must be more than a one-size-fits-all

Freya’s approach to treatment is guided by an understanding of the neurobiological mechanisms that are key in sexual excitation and inhibition. Our flagship product, Lybrido, is designed for patients with FSIAD who are relatively insensitive to sexual cues. Lybrido was developed from 15 years of research, and our clinical studies have shown statistically and clinically relevant improvements in women’s sexual experiences with its use.

Read more about the science behind Lybrido

Our products

Women's sexual health is complex - treatments for fsiad must be more than a one-size-fits-all

Freya’s approach to treatment is guided by an understanding of the neurobiological mechanisms that are key in sexual excitation and inhibition. Our flagship product, Lybrido, is designed for patients with FSIAD who are relatively insensitive to sexual cues. Lybrido was developed from 15 years of research, and our clinical studies have shown clinically relevant and statistically significant improvements in women’s sexual experiences with its use.

Read more about the science behind Lybrido

Our products

Upcoming events

Bio International Convention
June 13-16, 2022 | San Diego, US

Biopharm America
September 28-29, 2022 | Boston, US

Bio-Europe
October 24-26, 2022 | Leipzig, Germany

Women's experiences withFemale Sexual Interest/Arousal Disorder

Low desire is the most commonly
reported sexual complaint among women
(Laumann et al. 1999, Laumann et al. 2005,
Shifren et al. 2008, McCabe et al. 2015,
Zheng et al. 2016)

Many women don’t know that
low sexual desire is a 
treatable medical condition 
(Kingsberg 2014)

Women’s options for sexual disorder
treatments are more than
20 years behind options for men

Upcoming events

Bio International Convention
June 13-16 | San Diego, US

Biopharm America
September 28-29, 2022

Bio-Europe
October 24-26,2022 | Leipzig, Germany

Contact us for more information

Freya Pharma Solutions B.V.
Kraanspoor 50 | 1033 SE Amsterdam | The Netherlands

info@freyapharmasolutions.com 

© Freya Pharma Solutions. All rights reserved.
Contact us for more information

Freya Pharma Solutions B.V.
B.V. Kraanspoor 50 | 1033 SE Amsterdam | The Netherlands

info@freyapharmasolutions.com

© Freya Pharma Solutions.
All rights reserved.